Bioforum Deploys PhaseV AI Platform to Boost Clinical Trial Innovation

What Happened

Bioforum, a global clinical research organization, has announced it will implement PhaseV’s artificial intelligence-powered clinical trial design platform. PhaseV’s technology leverages AI and advanced analytics to optimize trial protocols, improve data collection, and enable adaptive study design. The collaboration is intended to streamline clinical research processes and enhance the likelihood of trial success, benefiting sponsors, researchers, and patients alike. With Bioforum’s adoption, more CROs are showing increased interest in AI-driven solutions to address challenges in trial efficiency and regulatory requirements. The partnership was revealed via a press release, with Bioforum set to integrate PhaseV’s AI platform across its research operations.

Why It Matters

The growing adoption of AI in clinical trials signals a transformation in how studies are designed and managed, with potential to accelerate drug development and reduce costs. Bioforum’s move highlights the expanding role of artificial intelligence in life sciences, setting a precedent for other research organizations. Read more in our AI News Hub